On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Cellceutix Corp. (CTIX.OB) Offers Hope to Cancer Industry and Opportunity to Investment Community

Lung cancer is still the number one cause of cancer death among men and women in the United States. Projections for 2010 by the American Cancer Society include over 220,000 new cases of lung and bronchial cancers with nearly 160,000 deaths as a result of lung cancer. If projections hold true, the number of new cases will be greater than the 173,770 cases that were reported in 2004. Another interesting fact is that, while leveling in the last several years, the number of deaths among women attributed to lung cancer has not seen a significant decline with the other major lines of cancer since 1990. Projections for 2010 have the number of deaths in women from lung cancer being approximately 10% greater than breast, colon and rectum cancers combined.

Lung carcinomas have proven to be very resilient with a great ability to adapt to chemotherapy treatments and still present a great area of need for new therapies. Multi-drug resistance, the principal mechanism by which many carcinoma strains develop resistance to chemotherapy drugs, is one of the primary reasons for ineffectiveness of standard cancer therapies on the market today. Cellceutix Corporation (CTIX.OB) trades on the NASDAQ Bulletin Board in the area of $.60 per share and is making significant strides with Kevetrin, their lead compound in development for treatment of multi-drug resistant cancer strains of the lung, breast and colon. Cellceutix is compiling the final data from pre-clinical toxicology studies to file an Investigational New Drug (IND) application with the USFDA in preparation for human trials of Kevetrin. Cellceutix plans to ask for the application to be “fast tracked” to expedite the procedure.

Cellceutix has developed and researched Kevetrin from the ground up with very promising results in pre-clinical studies. The latest pharmacology studies were released last week with the data coinciding with all other previous research. Kevetrin has already received accolades from posters being presented by Cellceutix at the American Association for Cancer Research (AACR). The AACR is considered by most to be the leading institute for cancer research in the world today. A poster on Kevetrin was highlighted at the AACR’s “Frontiers in Basic Cancer Research Meeting” in Philadelphia in October 2009. Research on Kevetrin has demonstrated success in more than 5,000 small animal tests, achieving significant delays in tumor growth compared to controls in multi-drug resistant lung, breast and colon cancer cell lines. The data also showed that a second cycle of Kevetrin continued to delay tumor growth without any development of resistance.

From an investment standpoint, Cellceutix has a very low market cap of around $40 million. There is a large insider holding ratio (approximately 50%) and a low float of approximately 40 million shares available for free trading. The Cellceutix management has been primarily funding operations independently without dilution of the share structure. It is apparent that they feel strongly their company’s compounds can reap great rewards in the future.

Leo Ehrlich, Chief Financial Officer of Cellceutix, stated, “When talking about a successful approved drug for resistant cancers, you must realize that you are talking about revenue possibilities into the billions of dollars. Presently, this is one of the most sought areas of drug development or acquisition by big pharma. ”

Mr. Ehrlich said, “Just over the last month we were contacted and invited by a major pharmaceutical company and a major financial institution interested in learning more about Cellceutix. Nothing is ever a complete certainty, but we anticipate continued success and the true value of our company to continue to be realized.”

The CTIX price per share has been steadily increasing this year with a 2010 low of $.20 and presently trading at $.66. To learn more about Cellceutix, Kevetrin and the investment opportunity Cellceutix presents, please visit the Cellceutix website at www.cellceutix.com.

Let us hear your thoughts: Cellceutix Corp. Message Board

Archives

Select A Month
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered